Akademik Veri Yönetim Sistemi
MUSCLE & NERVE, cilt.73, sa.6, ss.1118-1127, 2026 (SCI-Expanded, Scopus)
Introduction/Aims Eplontersen is approved in multiple regions for adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This exploratory analysis was conducted to evaluate the treatment effect of eplontersen by sex in patients with ATTRv-PN from the NEURO-TTRansform trial (NCT04136184). Methods Participants in NEURO-TTRansform who received >= 1 dose of eplontersen were included in this analysis; participants in the inotersen reference group who switched to eplontersen were excluded. Eplontersen was evaluated in the overall patient population and in a subgroup with cardiomyopathy. Change from baseline in the NEURO-TTRansform primary endpoints of serum transthyretin (TTR) levels to Week 65, modified Neuropathy Impairment Score +7 (mNIS+7) composite score to Week 66, and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) total score to Week 66 were evaluated. A historical placebo group from the NEURO-TTR trial (NCT01737398) was included as a control. Results The eplontersen group comprised 100 (69.4%) male and 44 (30.6%) female patients. The placebo group comprised 41 (68.3%) male and 19 (31.7%) female patients. For both sexes, treatment with eplontersen decreased serum TTR levels by > 80% (vs. reductions of 3%-13% with placebo), maintained mNIS+7 scores, and improved Norfolk QoL-DN scores (vs. deterioration with placebo). The treatment effect of eplontersen was similar in male and female patients with cardiomyopathy. Discussion Eplontersen halted neuropathy impairment and improved quality of life versus placebo to a similar degree in both male and female patients with ATTRv-PN, including those with cardiomyopathy. These findings support the use of eplontersen as an effective treatment for ATTRv-PN regardless of sex.